News & Opinion

A $38.7 million project in the European Union — the largest single grant for autism research in the world — aims to bring together academic labs and pharmaceutical companies to speed the move from basic to clinical research.

Preliminary results from a placebo-controlled trial of the antibiotic minocycline in children with fragile X syndrome suggest the drug alleviates some aspects of the disorder, according to research presented Friday at the International Meeting for Autism Research in Toronto.

Neuroscience funding has plateaued, so researchers need to squeeze every drop from existing data.

Long-term treatment with antipsychotic drugs and mood stabilizers can change the structure of the brain.

By studying pregnant women who already have a child with autism, researchers hope to understand how epigenetic changes — those that affect gene expression but don’t directly alter DNA — during pregnancy influences risk of the disorder.